Respiratory infections in the cystic fibrosis lung {#s1}
==================================================

Chronic obstructive lung disease remains the primary cause of mortality and morbidity in CF (Cutting, [@B20]). The defective function of the Cystic Fibrosis Transmembrane Conductance Regulator (*CFTR*) gene initiates a lifelong cycle of neutrophilic inflammation, progressive bronchiectasis, mucus obstruction and recurrent microbial infection of the CF airway. These processes typically begin in the first years of life and lead to eventual lung failure during early adulthood. The CF airway environment is vulnerable to colonization by particular bacterial and fungi species including *Haemophilus influenzae, Staphylococcus aureus, Aspergillus fumigatus*, and *Pseudomonas aeruginosa* (Gangell et al., [@B36]). Infection by these common pathogens typically trigger neutrophilic responses, however, these fail to eradicate the infection and lead to a sustained release of oxidants and proteases, particularly neutrophil elastase (NE) (Hartl et al., [@B42]; Painter et al., [@B63]). This neutrophil-based inflammation has been associated with the progression of structural abnormalities specifically bronchiectasis and air trapping, from as early as 3 months of age (Mott et al., [@B60]; Sly et al., [@B76]).

In addition to colonization by bacteria and fungi, the CF airway will be infected with respiratory viruses and viral infections are a major cause of PEx in the pediatric CF population (Goffard et al., [@B40]; Dijkema et al., [@B25]). The significance of viral infections in CF has been identified by the advancements in molecular diagnostic technologies to detect virus (Wat, [@B91]). The prevalence of respiratory viruses during CF PEx can vary from 5% up to 60% (Billard et al., [@B6]) and include; rhinovirus (RV), influenza A and B, respiratory syncytial virus (RSV), parainfluenza (PIV; Type 1--4), metapneumovirus, coronavirus and adenovirus (Waters and Ratjen, [@B93]; Flight and Jones, [@B33]). Earlier work suggested influenza viruses (A & B) (Pribble et al., [@B66]; Hiatt et al., [@B45]) and RSV (Abman et al., [@B1]; Armstrong et al., [@B3]) were the major cause of PEx in CF. However, studies utilizing more sensitive virological methods in the last 5 years have comprehensively established RV as the most common respiratory virus detected in CF airway (Burns et al., [@B12]; Wark et al., [@B90]; Kieninger et al., [@B50]; Etherington et al., [@B30]; Dijkema et al., [@B25]; Stelzer-Braid et al., [@B81]). Despite numerous studies into the virology of CF airways, the mechanistic link between virus infection, airway inflammation and structural lung disease remains largely unknown. Further investigation into the interaction of these disease components is warranted.

Impact of RV infection in CF lung {#s2}
=================================

A member of the *Picornaviridae* family within the Enterovirus genus, RV features a positive sense single stranded RNA genome \~7.2 kb in length. The airway epithelium is the primary site of RV infection and replication (Vareille et al., [@B87]). As reviewed by Palmenberg and Gern ([@B65]), 11 viral proteins form the non-enveloped icosahedral structure. The external capsid proteins comprise of VP1, VP2, VP3, while VP4 is located between the interface of capsid protein and RNA genome. These capsid proteins feature a high degree of heterogeneity and consequently the significant antigenic diversity among RV has precluded vaccine development (Glanville and Johnston, [@B39]; Lewis-Rogers et al., [@B54]). Currently, there are more than 150 serotypes of RV, which have been classified into 3 species; RV-A, RV-B, and RV-C. Within RV-A and RV-B, strains are clustered into major and minor RV groups based upon their specificity for the intracellular adhesion molecule (ICAM-1) receptor or low-density lipoprotein receptor (LDLR), respectively (Palmenberg, [@B64]). Recently, the cell receptor for RV-C species has been putatively identified as cadherin related family member 3 (CDHR3), whose expression is largely confined to ciliated cells (Bochkov et al., [@B9]; Griggs et al., [@B41]; Palmenberg, [@B64]).

Rhinovirus infections occur all year round and children experience on average six to eight episodes per year (Worrall, [@B95]). Although the "common cold" is largely self-limiting, it still poses a burden on the activity and productivity of the general population (Stein, [@B79]). Additionally, RV infection has a more pronounced effect on vulnerable individuals such as children with CF, as summarized in Table [1](#T1){ref-type="table"}. These include increased PEx (Asner et al., [@B4]), more severe respiratory symptoms (Burns et al., [@B12]; Wark et al., [@B90]), greater inflammation (Kieninger et al., [@B50]), reduced quality of life and hospitalization and prolonged antibiotic treatment (Smyth et al., [@B77]). Prevalence and symptoms of RV infection in patients with CF can vary between cohorts (reviewed by Billard et al., [@B6]), with some reporting similar rates of RV detection in both children with and without CF (de Almeida et al., [@B22]; Esposito et al., [@B29]), while others have reported significant correlations with disease progression in those with CF (Hiatt et al., [@B45]; van Ewijk et al., [@B86]). Other features such as age preference, RV serotype, viral load, impact on lung function were assessed in several studies. Susceptibility to particular RV serotype in children with CF requires further investigation due to inconsistent observations (de Almeida et al., [@B22]; Shah et al., [@B74]). RV load has been observed to be significantly higher in children with CF (\>100 times) when compared to healthy controls and children with asthma (\>10 times; Kieninger et al., [@B50]). This study also illustrated that viral load was negatively correlated to pulmonary function (Kieninger et al., [@B50]). Cousin et al. ([@B18]) observed that RV-induced PEx in children with CF resulted in failure of pulmonary function recovery for up to 6 weeks. An age preference for RV-associated CF exacerbations has also been reported for young children \<5 years old (Stelzer-Braid et al., [@B81]). However, several other studies have detected a higher frequency of RV in upper and lower airway of adults with CF via screening of sputum and throat swabs (Etherington et al., [@B30]; Goffard et al., [@B40]). Adults with CF who have viral associated PEx have been shown to have worse lung function and require more days of intravenous antibiotic treatment (Flight et al., [@B34]; Goffard et al., [@B40]). Others have also reported that adult patients who are less responsive to treatment are re-admitted for a subsequent exacerbation within a shorter time frame (Etherington et al., [@B30]). Finally, Flight et al. ([@B34]) found that RV infection in adults is accompanied by an increased risk of PEx, prolonged antibiotic prescription, higher respiratory symptom scores and heightened level of C-reactive protein. As RV has a large clinical impact on those with CF, it is critical to elucidate how this virus alters host antiviral and inflammatory responses.

###### 

Summary of clinical studies and outcomes related to Human Rhinovirus infection in CF.

  **References**                 **Cohorts**                                                                                                                                                                  **Sample Type**                                                                                                **Virus Detection**                                                   **Clinical Data**                                                                                                                                                                                                                                                                                                                                                   
  ------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------- ---------------------------------------------------- ----------------------------------------- ------ ----- ------ ------ ------------------------------------------------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------------------------------------------- -------------------------------------------------------------
  Smyth et al., [@B77]           CF patients (mean age 7.9 years)                                                                                                                                             Nasopharyngeal Aspirate, Serum Specimen                                                                        44/157                                                                Virus Immunofluorescene, Culture, Serology and PCR   58                                        12     9     12     9      NR                                                                                          Higher than other virus induced exacerbation         Prolonged treatment                                                                      No Difference
  Collinson et al., [@B17]       CF patients (median age 7.3 years)                                                                                                                                           Nasopharyngeal Specimens                                                                                       51/119                                                                Virus Culture, PCR                                   41                                        NR     NR    NR     NR     NR                                                                                          Significantly lower                                  More oral and intravenous antibiotic treatments for those with more infection annually   No Difference
  Armstrong et al., [@B3]        80 infants diagnosed with CF before 12 months of age (31 infatns were hospitalized for persistent respiratory symptoms                                                       BALs/ Nasopharyngeal Samples                                                                                   14/26                                                                 Virus Immunofluorescene, Culture                     14.3                                      14.3   43    28.5   NR     NR                                                                                          NR                                                   Not for virus infection                                                                  Higher
  Hiatt et al., [@B45]           22 infants \<2 years of age with CF (30 patient-seasons) and 27 age-matched controls (28 patient-seasons) participated                                                       Nasopharyngeal samples                                                                                         26/150                                                                Serology, Culture Inoculation                        NR                                        30     23    17     17     27% Picornavirus                                                                            NR                                                   NR                                                                                       RSV infection CF infants has higher rate of hospitalization
  Olesen et al., [@B62]          75 children (media age 8)                                                                                                                                                    Sputum, Laryngeal aspirations                                                                                  96/606                                                                PCR                                                  87                                        3      2     6      2      NR                                                                                          Significantly lower (when excluding HRV infection)   8 patients received antibiotic treatments                                                NR
  Wat et al., [@B92]             71 CF patients (median age 9)                                                                                                                                                Nasal swabs and sputum samples                                                                                 63/138                                                                NASBA                                                15.9                                      15.2   2.9   10.9   NR     1% Coronavirus, 36.2% Any                                                                   NR                                                   NR                                                                                       NR
  de Almeida et al., [@B22]      103 CF patients (median age 8.9)                                                                                                                                             Nasopharyngeal aspirates and nasal mucus specimens, sputum and oropharyngeal samples                           203/408                                                               PCR                                                  34.1                                      1.2    3.7   0.6    0.2    5.9% Enterovirus, 5.6% Human Bocavirus, 4.7 Human Coronavirus, 0.7% Human metapneumovirus   NR                                                   NR                                                                                       NR
  Asner et al., [@B4]            112 CF patients                                                                                                                                                              Mid-turbinate swabs, sputum, throat swab                                                                       26/43                                                                 Immunofluroescene, multiplex PCR                     23                                        7.6    35    15.4   11.5   34.6% Coxsackie/echovirus, 15.4% Coronavirus, 7.7% Human Metapneumovirus                    No Difference                                        No Difference                                                                            No Difference
  Stelzer-Braid et al., [@B80]   37 Participants (median age of 11.4) with CF                                                                                                                                 Nasal swabs and sputum samples                                                                                 17/37                                                                 Multiplrc PCR                                        35                                        2.7    2.7   10.8   NR     2.7% Metapneumovirus; 46% has more than one viral or bacteria pathogen                      NR                                                   NR                                                                                       NR
  Kieninger et al., [@B50]       299 Children (median age 8.2). 195 children with CF (88 stable, 107 exacerbation), 40 children with Non CF Bronchiectasis, 29 children with Asthma and 35 Control Subjects   BALs                                                                                                           73/299                                                                PCR                                                  24.4                                      NR     NR    NR     NR     NR                                                                                          Inversely associated with RV load                    Increase use of antibiotic when increase respiratory symptoms were recorded              NR
  Goffard et al., [@B40]         46 patients (median age of 29)                                                                                                                                               Sputum                                                                                                         16/64                                                                 PCR                                                  24                                        3      3     3      NR     8% Coronovirus                                                                              No Difference                                        No Difference                                                                            NR
  Esposito et al., [@B29]        47 CF patients with acute pulmonary exacerbation (median age of 16.7) and 31 CF patients in stable clinical condition (median age of 17.3)                                   Nasopharyngeal Swabs                                                                                           23/78                                                                 PCR                                                  61                                        17.4   4.3   NR     NR     8.6% Bocavirus, 4.3% Metapeumovirus, 4.3% Enterovirus                                       No Difference                                        NR                                                                                       NR
  Etherington et al., [@B30]     180 patients participated ion treatment with intravenous antibiotics for an acute pulmonary exacerbation. 42 patients (media age 26.5) with positive viral detection         Viral Throat Swabs                                                                                             42/432                                                                PCR                                                  69                                        19     2.4   4.8    2.4    2.4% Metapneumovirus                                                                        Significantly Lower                                  Intravenous antibiotic for longer period                                                 NR
  Flight et al., [@B34]          100 adults with CF (median age of 28)                                                                                                                                        Sputum, Nose Swabs and Throat Swabs                                                                            191/626                                                               PCR                                                  72.5                                      6.1    2     2.5    4.1    13.2% Human Metapneumovirus                                                                 Lower acute fall in FEV1                             Increase number of prescription                                                          NR
  Dijkema et al., [@B25]         20 Children with CF (0--7 years) and age matched healthy control                                                                                                             Nasopharyngeal Swabs                                                                                           161/352 (only HRV was tested)                                         Nested PCR, Southern Blotting and Sequencing         45.7                                      NR     NR    NR     NR     NR                                                                                          NR                                                   Increase use of antibiotic prophylaxis                                                   NR
  Stelzer-Braid et al., [@B81]   110 children with CF                                                                                                                                                         upper (nasal swab, oropharyngeal suction, and sputum) and lower (bronchoalveolar washings) respiratory tract   59/263 (\<5 years old); 23/202 (older children) only HRV was tested   PCR, Nested PCR                                      43% (\<5 years old); 12% older children   NR     NR    NR     NR     NR                                                                                          NR                                                   NR                                                                                       NR

Airway epithelium and RV infection in CF {#s3}
========================================

A pseudostratified epithelium lines the surface of the lung (trachea, primary bronchi, secondary bronchi, tertiary bronchi, and bronchioles) and is composed of several cell types including ciliated cells, basal cells, secretory cells and goblet cells. These airway epithelial cells form the first point of contact with inhaled environmental insults, including respiratory viruses. To provide a physical barrier against particulates/pathogens from entering the lung tissue, numerous cell-cell connections are formed including tight junctions, adherent junctions, gap junctions, and desmosomes (Whitsett and Alenghat, [@B94]). To clear inhaled particles/pathogens, intraepithelial goblet cells, and submucosal glands mucous cells secret mucins. These large glycoproteins bind matter including microbes and allows effective cough clearance by the mucociliary escalator (Foster, [@B35]). Mucins are transported from the bronchioles to the trachea via beating cilia, expressed by airway epithelial cells of the luminal airway surface (Ma et al., [@B56]).

Perhaps more significantly for viral pathogens, the airway epithelium plays a crucial role in innate immunity. It has been suggested that the inflammatory responses induced by airway epithelial cells give rise to associated clinical symptoms (Jacobs et al., [@B47]). RVs can disrupt epithelial tight junctions including zona occludens 1 (ZO-1) protein by stimulating the production of reactive oxygen species (ROS) during viral replication (Unger et al., [@B85]). Work utilizing airway epithelial cells *in vitro* have shown reduced expression of other tight junction proteins, loss of epithelial integrity, disruption of extracellular matrix and subepithelial fibrosis and induction of proangiogenic molecules which enhance angiogenesis and airway remodeling (Bossios et al., [@B11]; Leigh et al., [@B53]; Bochkov et al., [@B8]; Tacon et al., [@B83]; Yeo and Jang, [@B96]; Looi et al., [@B55]).

The uptake of RV via clathrin-dependent or -independent endocytosis or through micropinocytosis occurs when RV binds to its specific receptors. Upon binding and in a low-pH environment, uncoating of RVs occurs and the virus undergoes conformational changes. The loss of the protein capsid protein VP4, and the externalization of the hydrophobic N-terminal of VP1, facilitates RVs to cross the host cell membrane (Jacobs et al., [@B47]; Blaas and Fuchs, [@B7]). Following viral uncoating and membrane rupture, RV "pathogen-associated molecular patterns" (PAMP) are recognized by the host cell via interaction with pattern recognition receptors (PRRs) including; Toll like receptors (TLRs), C-type lectin receptors (CLRs), retinoic acid-inducible gene 1 (RIG-I)-like receptors (RLRs), and nucleotide-binding oligomerization domain-like receptors (NLRs). The signaling pathways induced by TLRs and RLRs are typically host defense antiviral pathways as well as the production of antiviral substances, namely IFNs, B-defensins (Proud et al., [@B67]), and nitric oxide (Sanders et al., [@B71]). The airway epithelium also responds to RV infection by activating pro-inflammatory signaling pathways which trigger the release of chemokines and cytokines including IL-8, RANTES/CCL5, and granulocyte-macropahge colony-stimulating factor (GM-CSF), that in turn recruit neutrophils, esoinophils, natural killer cells (NK cells), and macrophages to the infected tissue. IL-6 has an important role in innate immune responses induced by RV infection and IL-6 production has been shown to be inversely correlated to cold symptoms scores and disease severity (Doyle et al., [@B27]). IL-15 exerts important antiviral and cytotoxic effects and is involved in the activation, differentiation, survival and recruitment of NK cells and CD8+ T cells (Jayaraman et al., [@B48]). IL-8 has been associated with RV infection as well as cold symptom scores (Gern et al., [@B37]). Furthermore, it has also been associated with neutrophilic infiltration in sputum (Gern et al., [@B38]). Taken together, it is evident that innate immune signaling induced by the airway epithelium is essential for effective antiviral responses.

However, in many chronic airway diseases including CF, antiviral responses are defective. Due to the pre-existing genetic defect, normal functions of the CF airway epithelium are often disrupted. As the primary site for virus entry and replication during viral infection, understanding the consequence that lack of CFTR function has on pathophysiology during virus infection is critical for effective disease management. Relevant *in vitro* experimental studies investigating RV infection in CF epithelium have been summarized in Table [2](#T2){ref-type="table"}. Most studies performed to date assessed cells obtained from adult CF cohorts who had significant disease and structural lung damage. These studies report similar levels of interferon production post infection despite higher viral load being detected (Chattoraj et al., [@B15]; Dauletbaev et al., [@B21]). Studying cells from pediatric CF cohorts may generate more relevant data and potentially reveal new insights into early life RV infections that could be exploited therapeutically. Also important is the level of pro-inflammatory cytokines produced by CF epithelium following RV infection. Many studies have reported similar level of IL-8, IL-6, type I, and III IFN production, while others reported higher level of production dependent on virus strain and infectious titer (Table [2](#T2){ref-type="table"}). These contradictory observations may be due in part to the age of patients involved, disease severity, RV strain, dose, and length of infection. Most studies to date including ours have focused on specific host response targets at the gene or protein level which might not reflect the global innate immune changes during RV infection. The translation of such a targeted approach would be the identification of a single molecule to address a single pathway and ultimately target one downstream effect such as the production of a single cytokine. However, knowing that the interaction of RV and the airway is multifaceted, an alternative approach that addresses this complexity is needed.

###### 

Summary of *in vitro* studies of Human Rhinovirus infection in CF Airway Epithelium.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Subject**                                     **Sampling Sources**      **RV Serotype**   **Inoculation Dose**   **Viral Load**                            **Other Pathogens**             **Antiviral Cytokines**                                                                                     **Inflammatory Cytokines**                                                               **Apoptosis**                                           **References**
  ----------------------------------------------- ------------------------- ----------------- ---------------------- ----------------------------------------- ------------------------------- ----------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------- ---------------------------
  Adult CF (16--33 years)                         BEC (ALI)                 RV39              3 × 10^6^ TCID~50~     10^4^ TCID50/mL Similar to normal cells   *Pseudomonas aeruginosa* (PA)   RV: IFNβ, λ1, 2 mRNA and protein ↑\                                                                         RV: IL8 mRNA ↑\                                                                          Not measured                                            Chattoraj et al., [@B15]
                                                                                                                                                                                               Similar to normal cells\                                                                                    RV + PA: IL-8 mRNA ↑↑\                                                                                                                           
                                                                                                                                                                                               RV + PA: IFNβ, λ1, 2 mRNA and protein ↓\                                                                    Similar to normal cells                                                                                                                          
                                                                                                                                                                                               Only in CF cells                                                                                                                                                                                                                                             

  Adult CF (19--41 years)                         BEC from explant lung     RV16              MOI 0.1                \>10^4^ copy number Higher in CF          *Pseudomonas aeruginosa* (PA)   RV: IFNβ mRNA↑\                                                                                             RV: IL8 mRNA ↑\                                                                          Not measured                                            Dauletbaev et al., [@B21]
                                                                                                                                                                                               Similar to normal cells; OAS1 mRNA↑\                                                                        Similar to normal cells                                                                                                                          
                                                                                                                                                                                               Similar to normal cells                                                                                                                                                                                                                                      

  Young children with CF (1--7 years)             AEC                       RV1b              MOI 3, 25              \~1500 copy/ng RNA                        No                              Not measured                                                                                                IL-6 and IL-8 protein ↑ in CF cells only for infection with RV1b of MOI 25 at 48 hours   Reduced compared to normal cells                        Sutanto et al., [@B82]

  Children and adults with CF (4.5--48.9 years)   NEC, BEC and cell lines   RV16, RV1b        MOI 2                  Not measured                              No                              Not measured                                                                                                IL-6, IL-8, IP-10, MCP-1, RANTES↑\                                                       Similar apoptosis, ↑necrosis compared to normal cells   Kieninger et al., [@B50]
                                                                                                                                                                                                                                                                                                           Similar to normal cells                                                                                                                          

  Children with CF (3--11 years)                  BEC                       RV16, RV1b        MOI 4                  Not measured                              No                              RV16: ↓ IFNs (IFN-λ1, IFN-λ2/3 and IFN-β), PRRs (RIG-1 and MDA-5) and ISGs (PKR, OAS1, viperin and MxA).\   ↑ CXCL8/IL-8, IL-6 and CXCL10/IP-10                                                      Not measured                                            Schögler et al., [@B72]
                                                                                                                                                                                               RV1b: ↑ PRRs (TLR3 and RIG-1) and IFN pathway (IFN-λ1 and IFN-λ2/3 compared to normal cells                                                                                                                                                                  
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*AEC, Airway Epithelial Cells; BEC, Bronchial Epithelial Cells; NEC, Nasal Epithelial Cells*.

Past and current therapies {#s4}
==========================

To date, there have been no studies performed that have focused on potential treatments for RV infection in CF individuals. As RV continues to be the most prevalently detected virus in the all individuals including CF airway, additional evidence is needed to specify its connection with the existing factors such as lack of CFTR and airway inflammation through molecular intermediates and cellular signaling pathways. Common anti-inflammatories including oral corticosteroids and high-dose ibuprofen are unsuitable for treatment in infants and preschool children due to their long-term side effects (Lai et al., [@B51]; Fennell et al., [@B32]). Azithromycin may have some interesting antiviral properties, specifically in reducing RV replication via amplification of the IFN pathway-mediated antiviral responses (Schögler et al., [@B72]). Nevertheless, clinical studies are necessary to elucidate the clinical impact of azithromycin against RV-induced PEx in patients with CF. Vaccination is an important part of CF clinical care, however vaccine development for RV has been rather challenging due to the wide range of antigenic diversity of more than 150 serotypes of RV across three different strains. Technical difficulties in producing sufficient amounts of antigen against multiple RV serotypes using animal models (as reviewed in Del Vecchio et al., [@B23]) also remains a challenge and as result, the development of a long-lasting RV vaccine has not been successful. This has been further compounded by the lack of a suitable model (other than human) that is fully permissive to RV infection as well as insufficient clinical data to identify and prioritize dominant RV serotypes. In addition, no suitable animal models for CF exhibit complete spectrum of CF phenotype besides CF pig and ferret which are strictly limited for research use (as reviewed in Rosen et al., [@B68]).

Since vaccination is unavailable, other approaches have been explored in healthy and disease cohorts other than CF. An early approach by Turner et al. ([@B84]) aimed to prevent HRV binding to its receptors via administration of inhaled recombinant soluble ICAM-1 (Tremacamra). Although the reduction in symptom severity and viral shedding were promising, the high costs and dosing regimen recommended (6 times daily) made translation of this therapy into the clinical setting prohibitive (Turner et al., [@B84]). Targeting viral replication has perhaps been the highest priority in past therapeutic development, where capsid-binding drugs bind to the hydrophobic "pocket" of the viral capsid (reviewed in McKinlay et al., [@B57]). Pleconaril and Pirodavir were discontinued due to unforeseen side effects and drug efficacy. Reformulated Pleconaril and Vapendavir have completed clinical trials although results have yet to be published \[ClinicalTrials.gov (NCT00394914 & NCT01175226)\]. A recently discovered compound IMP-1088 offers more promise (Mousnier et al., [@B61]). This molecule was shown to inhibit human N-myristoyltransferases NMT1 and NMT2, prevent virus assembly and suppress RV replication and infection across various RV strains without inducing cytotoxicity. However, most of this work was demonstrated using cell lines or adult primary cells and further assessment of IMP-1088 on primary cells from young children with CF is necessary. The outcome of such studies would be informative as to whether this compound exerts similar efficacy across all cohorts, as more than 30 polymorphic DNA loci associated with host variation in gene expression called responsereQTLs to rhinovirus infection has been previously reported (Çalişkan et al., [@B13]).

Alternatively, the roles of type I IFN administration in enhancing the primary antiviral signaling pathway of innate immunity have also been assessed. Early studies involving the prophylactic administration of IFN-α2 or IFN-β were found to demonstrate a reduction in number of RV-induced episodes but no difference in symptom severity or duration (Farr et al., [@B31]; Hayden et al., [@B43]; Monto et al., [@B58]; Sperber et al., [@B78]). Multiple side effects from high dose administration of IFNs, including nasal bleeding, transient leukopenia and sore throat have also been reported (Sperber et al., [@B78]). A more recent study assessed low dose IFN-β administration and although antiviral activity was enhanced, it did not aid in reducing cold symptoms of viral induced exacerbations asthma cohorts (Djukanović et al., [@B26]). Ruuskanen et al. ([@B69]) also suggested that short-term subcutaneous pegylated IFN-α in combination with oral ribavirin treatment rapidly decreased RV RNA in recurrent or chronic rhinovirus infection in immunocompromised patients.

Alternative therapies have not been thoroughly assessed in CF cohorts. While ongoing clinical trials are comprehensive in evaluating the efficacy of CFTR potentiators and correctors for application on mutation specific patients, improvements in infection and inflammation therapies would be highly desirable for all individuals with CF. Indeed, Ivacaftor has been found to reduce sputum *P. aeruginosa* density (\>60-fold) and airway inflammation significantly (Hisert et al., [@B46]). Whether improvements in CFTR folding or function will enhance antiviral responses in children with CF warrant further investigation. Multi-target drug design also holds potential and could be employed to exert both antiviral and anti-inflammation effects. Understanding how host anti-viral and inflammatory responses differ in CF airways, particularly young children, is critical in facilitating the development of new therapeutic treatments that can limit CF disease progression.

New therapeutic for RV infections {#s5}
=================================

Current therapies directed at RV are mainly focusing on specific viral proteins or inhibition of viral cycle. However, some of these drugs are not effective on drug-resistant viral strains. The current review proposes an alternative approach that focuses on host cellular pathways and factors. To expedite novel therapeutic strategies, investigation on how cellular signaling pathways can be altered by RV infection and how these alterations can be manipulated by new compounds or drugs are crucial for new therapeutic development. The current field of system biology and adoption of high-throughput technologies through transcriptomics not only facilitates characterization of the host-pathogen interaction in a more comprehensive manner, but also aids in understanding how developed and repurposed compounds exert their antiviral properties on RV infection in CF patients.

Knowing viruses can manipulate the host signaling processes and thus altering the host-pathogens interactions (Christiaansen et al., [@B16]), evaluating the global changes in gene expression during infection via employing gene/transcriptomics could elucidate crucial messages for therapeutic target identification. Transcriptomics is used to study the total RNA output of a cell. Early transcriptomic analyses were performed using microarrays which have customized probes, while current transcriptomic analyses rely on high-throughput RNA sequencing which capture global transcriptome (Mortazavi et al., [@B59]). These techniques allow analysis for "all molecules" regulated at the gene level. By illustrating their interaction within the cells and the complexities of host-pathogen interactions, enhancing or diminishing specific molecules as well as precise characterization of specific targets can be a more promising therapeutic approach (as reviewed in Cesur and Durmuş, [@B14]). Generally, computational approaches are used to organize or manage these data sets and interpret the biological inference, including network analysis (such as InnateDB, NetworkAnlayst, and Cytoscape) and pathway analysis (such as Reactome, Kegg Pathway, and Pantherdb).

In the context of host-viral interaction, transcriptomic analysis has been successfully applied to identify the uncharacterized isoforms from wild-type dengue infected host RNA from human hepatoma cells. The authors demonstrated that infection with wild-type dengue virus elicited a different host response compared to infection with a vaccine sensitive strain, highlighting the potential of strain-specific responses (Sessions et al., [@B73]). Transcriptional profiling of blood specimens from symptomatic and asymptomatic patients with RV infection have revealed that individuals with active infection demonstrate a robust transcriptional signature of immune-related genes (Heinonen et al., [@B44]). In other disease settings including asthma and allergic rhinitis, transcriptomic responses of human respiratory cells to surrogate RV infection \[Poly(I:C) stimulation\] have potentially identified disease-specific signatures (Wagener et al., [@B89]). Therefore, it is imperative to assess the global transcript expression and investigate the host-viral interaction, given that CF is a defined genetic disease condition and live RV infection can truly represent an active infection which might involve modification of the host response. This approach is not only applied to protein-coding RNA but also provide insights to critical non-coding RNA such as short non-coding RNAs (miRNAs) and long non-coding RNAs (lncRNAs) which are key regulators for modulation of gene expression (Delpu et al., [@B24]).

Mapping genes on a complete network allows identification of key hub genes and central genes with high connectivity which exert large effects on signal transduction. Molecular network analysis also allows enrichment of functional modules to identify which area group of genes are cooperatively working together to perform specific biological function and could be associated with disease setting (reviewed by Csermely et al., [@B19]). Some examples include, the identification of 16 strongly connected hub genes as potential antifungal drug targets against *Candida albicans* (Altwasser et al., [@B2]), the identification of new key genes for type 1 diabetes (Safari-Alighiarloo et al., [@B70]) as well as certain cancers (Zaman et al., [@B97]; Jin et al., [@B49]). Moreover, omics data has discovered disease modules and revealed substantial inter-patient heterogeneity, highlighting the potential importance of customize treatments to conditions. Numerous algorithms have been introduced to identify disease modules, including ModuleDiscoverer that identified a rodent model of non-alcoholic steatohepatitis (NASH), as well as a severe form of non-alcoholic fatty liver disease (NAFLD) (Vlaic et al., [@B88]). To maximize the efficacy and treatment outcome, patient individual characteristics, including their genetic profile needs to be considered. Although using biological network analysis can expedite the drug discovery process, the timeline from target identification to clinic application can still be lengthy.

An alternative strategy is to explore drug repurposing. Integrated analysis of disease-gene profiles, pathway analysis, and mining of FDA approved drug databases can be carried out to identify correlations of common pathways with certain compounds or molecules at the network level. Successful examples of drug repurposing based on transcriptomic analyses include the identification of topiramate for the treatment of inflammatory bowel disease (IBD) and cimetidine for the treatment of lung adenocarcinoma (Dudley et al., [@B28]; Sirota et al., [@B75]). Using a large-scale expression signature, Lee et al. ([@B52]) have also identified that ivermectin, trifluridine, astemizole, amlodipine, maprotiline, apomorphine, mometasone, and nortriptyline show significant anti-proliferative activity against glioblastoma. With the recent establishment of ImmPort, a data repository that promotes research dataset repurposing (Bhattacharya et al., [@B5]), the identification of novel targets and repurposed drugs that target these has been accelerated further. Currently, there is paucity of data in CF-related RV-therapy given its impact on CF lung disease and thus new interventions are urgently required. The strategy to repurpose already approved drugs could advance antiviral therapies by reducing cost and improving and quality of life for affected individuals.

Conclusion {#s6}
==========

RV infection remains a significant cause of pulmonary exacerbation in CF. There has been little investigation into antiviral therapies in CF especially in young children who are more susceptible to these types of infection. However, modern virological procedures and omic technologies now facilitate more in-depth studies of the genes and molecular pathways involved in aberrant CF antiviral responses to RV. We propose transcriptomics could be leveraged to elucidate future therapeutic intervention for treatment of rhinovirus infection in CF. For example, a global gene expression profile of bronchial epithelial cells from patients with CF, under baseline conditions and after RV infection will be profiled following next-generation RNA sequencing (Figure [1](#F1){ref-type="fig"}). Sequences can be aligned and mapped to already available reference genomes to identify differentially expressed genes pre- and post-infection. The identified genes could then be annotated using online repositories or libraries to investigate their enriched functional biological pathways. Moreover, networks or subnetworks can then be constructed by mapping identified genes to explore their relationship using curated protein-protein interaction databases. Therapeutic opportunities can also identify by exploring protein-protein interaction and protein-transcription factor, protein-drug interaction as well as chemical interaction databases. Finally, monolayer cell cultures which have previously been found to be more susceptible for RV infection (Bochkov et al., [@B8]) represent an oversimplified model for the multicellular interactions of epithelial (ciliated cells, goblet cells) and immune cells (dendritic cells, neutrophils). Indeed, functional validation utilizing human *in vitro* 3D airway models (Boda et al., [@B10]) will be needed to further elucidate to host-pathogen interactions. The emergence of single cell transcriptomics could be used to compliment 3D airway models and accelerate progress in this new era of scientific research. Overall, the advancement of these promising tools should aid in expediting new therapeutic intervention in this sphere.

![Proposed workflow using transcriptomics to elucidate future treatment for cold virus infection in CF.](fphar-09-01270-g0001){#F1}
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